A reunião anual de 2015 da Rede Global Biodiversity Heritage Library será realizada no Brasil e abordará o estado de desenvolvimento da Biodiversity Heritage Library (BHL) e sistemas de informação em Biodiversidade. Organizada pelos Programas SciELO e BIOTA da FAPESP, a reunião está dirigida para pesquisadores e profissionais relacionados com biodiversidade e informação científica. O programa científico contará com autoridades e especialistas nacionais e internacionais. A Rede Global da BHL (gBHL) conta com a participação da África do Sul, Austrália, Brasil, China, Egito, Estados Unidos e Europa. A BHL trabalha de forma colaborativa em prol do acesso aberto à literatura em biodiversidade como parte da comunidade de biodiversidade global.

1. © 2015 Butantan Institute - Reproduction forbidden without prior authorization
6th Global Biodiversity
Heritage Library

2. mission
To contribute to public health through research, innovation, production and
development of biological products, sharing knowledge with the society
vision
To be a world-class public institution dedicated to research, development,
dissemination, education and the manufacturing of biological products for public
health demands

3. 2.151direct employees
33% public employees
67% Foundation workers
~100outsourced employees
Instituto Butantan
Vaccine and Sera
Production
Scientific
Research &
Development
Cultural Center Other areas
Butantan
Foundation
organizational structure
Source: Instituto Butantan (Nov 2014)

4. ~750,000 m2 300,000 60%
in the heart of visitors/year preserved
the urban area green area
Butantancampus

5. 4
museums
biological museum
history museum microbiology museum
Emílio Ribas museum
Butantancampus

6. scientificresearch&developmentlabs
• 19 scientific labs
- Scientific Development Division [16 labs]
- Special Lab for Applied Toxinology - LETA [3 labs]
• Center of Biotechnology [8 labs]
• Hospital Vital Brazil [10 beds]
• Central Animal Facility
• 180 PhD researchers
• 500 graduate students
Sources: Instituto Butantan; ISI web of Science Feb2015
number of research articles and citations - 2011-2014
198
207
215
214
3.755
3.945
4.446 4.727
0
500
1.000
1.500
2.000
2.500
3.000
3.500
4.000
4.500
5.000
185
190
195
200
205
210
215
220
2011 2012 2013 2014
artigos publicados* citações totaisarticles citations

7. scientificresearch&developmentlabs
Labs
Arthropods
Bacteriology
Biochemistry
Biotechnology Center
Cell Cycle
Cellular Biology
Ecology and Evolution
Genetic
Herpetology
Immunochemistry
Immunogenetics
Immunopathology
Pain and Signaling
Parasitology
Pathophysiology
Pharmacology
Special Lab of Applied Toxinology
Viral Immunology
Virology
Zoological Collections
4 major areas
animal
biology
vaccinology development
toxinology

8. educationalprograms
• scientific knowledge courses
venomous animals; venomous insects; sera and vaccines; pharmacovigilance; amphibian
biology; introduction to microscopy, etc.
• more than 20 graduate extension courses
introduction to immunobiology; analytical tools applied to public health and environmental
management; microbiology practices; introduction to education in museums; etc.
• PAP - Professional Advancement
Program
Health sector professional training
• Scientific Initiation
scholarships for undergraduate students
participating in Butantan research projects
• MBA in Innovation
Trains professionals for the management
of critical functions of the innovation
process, promoting the creation of
mechanisms to facilitate technology
transfers.
• Inter-institutional Graduate Studies in Biotechnology
[University of São Paulo, Institute for Technological Research - IPT, Instituto Butantan]
• Graduate Studies in Toxinology
approved by CAPES in August 2010, with a grade of 5 (out of 7 points), for Masters and PhDs

9. antivenomproduction
horse immunization
São Joaquim Farm
50 km from São Paulo
~ 800 horses
22,000 liters of plasma/year

10. snake facility
~1,000 animals
- Bothrops - 5 species
- Crotalus - 2 subspecies
- Lachesis - 1 species
- Micrurus - 2 species
spider / scorpion facility
~ 15,000 animals
- Loxosceles spider (brown spider)
- Phoneutria spider (banana spider)
- Tityus scorpion (yellow scorpion)
caterpillar lab
~ 600 animals
- Lonomia caterpillar
venonforantivenomproduction

11. industrialcomplex-production
7 plants
• Anaerobic vaccines
- Tetanus and Botulism
• Bacterial Purification Center
• Aerobic Vaccines
- Diphtheria and Pertussis
• Hepatitis B
• Influenza
• Rabies
• Sera
1 Formulation and Filling Center
6 multifunctional pilot plants
o Dengue
o Rotavirus
o Recombinant BCG
o Monoclonal antibodies
o Influenza - H5N1
o Blood products

12. portfolioofserumproducts
13 immunoglobulins
400,000 vials/year
5 snake antivenoms diphtheria antitoxin
spider antivenom
caterpillar antivenom
tetanus antitoxin
botulism E antitoxin
rabies antiviral
botulism AB antitoxin
scorpion antivenom

13. portfolioofvaccines
6 vaccines of the national calendar
150 million doses per year
DTP
Diphtheria-Tetanus-Pertussis
(celular)
DT
Diphtheria-Tetanus
(for children)
dT
Diphtheria-Tetanus
(for adults)
rabies
hepatitis B
Influenza

14. distributionandnumbers
Hepatitis B
- 1st recombinant vaccine produced
in Brazil
- 100% produced by Instituto Butantan
- target audience (2013):150 million people
under the age of 49 years
(75,6% of the population)
- 800.000 carriers in Brazil
HPV
- 685,400 infected people/year
- 95% of the cases of cervical cancer
- second most common cancer in women
Sources: SINAN; website Portal da Saúde - SUS;
Ministry of Health (2013)
PNI – Programa Nacional de Imunizações
[National Immunization Program]
free of charge vaccination
5.570 cities - 27 states (all Brazilian states)
7 official vaccine manufacturers

15. Source: Ministério da Saúde, set 2014
423 m 384 m 1.4 b 845 m USD757 m 802 m 1.1 b
29%
42%
36%
40%
48%
40% 40%
21%
34%
39%
40%
15% 35% 32%
5%
5% 3%
4%
5%
4%
4%
2%
4%
5%
5%
11%
8% 7%
6%
4%
34%
11% 13%
6%
27%
12%
24%
0%
20%
40%
60%
80%
100%
120%
2008 2009 2010 2011 2012 2013 2014
%ofacquireddoses
Opas (17 vaccines)
Tecpar (1 vaccine)
Funed (1 vaccine)
FAP (1 vaccine)
Butantan (6 vaccines)
Bio-Manguinhos /
Fiocruz (9 vaccines)
doses328 m 306 m 452 m 311 m 211 m 230 m 235 m
Ministry of Health acquisitions
ProgramaNacionaldeImunizações-PNI

16. poisonousanimals
study of bioactive components of poisonous animals
pharmacological activities
• analgesic
• anti-inflammatory
• anticoagulant
• antitumor
• nervous system related action
• anti-hypertensive

17. patents
* others include: propolis extract, protein from
Leptospira, spider proteins, recombinant protein
for AIDS diagnosis, etc.
Lopap – 4 patents
Biolab / Fapesp
Amblyomin-X – 2 patents
União Química / Fapesp
Silica (SBA-15) – 1 patent
Cristália / Fapesp
patents quantity
vaccine 12
serum 3
immunotherapy 3
haemostasis 2
analgesic 2
peptide 2
tissue regeneration 2
anti cancer 1
antibody 2
others* 11
total 40
Pertussis low – 1 patent
Crotalphine – 2 patents
Biolab / Fapesp

18. pipeline
nr products description
1 Dengue Vaccine Attenuated tetravalent vaccine (serotypes DEN1, DEN2, DEN3, DEN4) –
Phase 2 of clinical trials
2 Rotavirus Vaccine Attenuated pentavalent vaccine (serotypes G1, G2, G3, G4, G9) –
Phase 2 of clinical trials
3 Pertussis low Vaccine B. pertussis whole cell with lower content of LPS
4 Pneumococcal Vaccine Inactivated non-encapsulated pneumococcal whole cell
5 DTPlow+HepB+Hib Vaccine Pentavalent - Diphtheria, Tetanus, Whooping cough, Hepatitis B and
Haemophilus Influenza type B
6 DTPlow+HepB+Hib+IPV+MenC Vaccine Heptavalent - Diphtheria, Tetanus, Whooping cough, Hepatitis B,
Haemophilus Influenza type B, Polio and Meningococcal type C
7 Hepatitis B + MPLA Vaccine For > 50 years old and immunocompromised persons
8 rBCG + Hep B Vaccine For neonates
9 Onco rBCG Vaccine For bladder cancer treatment
10 Adjuvant BpMPLA BpMPLA derived from LPS of B.pertussis to be combined to different vaccines
11 Bee’s Antivenom Treatment against multiple bee stings
12 Lung surfactant For neonates
13 Sílica (SBA-15) Adjuvant for orally administrated vaccines
14 Amblyomin-X Anticancer medicine, obtained from tick saliva
15 Crotalphine Potent analgesic drug from snake venom. Long-lasting analgesic (2-5 days)
16 Crotamin Cell penetrating peptide - Introduction of genetic materials into the cells, such as
DNA and RNA
17 Lopap Prothrombin Activator, anti-apoptotic activity and other pharmaceutical formulations
18 Monoclonal antibodies Anti-CD3 for transplantion rejection and other monoclonals for other uses
19 Hemoderivatives Production of IgG, factor VIII, IX, Albumin and other products

19. IIBB will
• be a center dedicated to research, innovation and generation of
innovative enterprises
• be located at a renovated building (35.000 m2)
• promote its own enterprises as well as joint ventures with public and private
institutions (domestic or international), through industrial, commercial and
corporate models suited to each kind of project
ButantanInstitutefor
InnovationinBiotechnology-IIBB
IIBB
conceptual
design

20. nationalandinternationalpartnerships
Harvard

21. Board of Directors - Instituto Butantan
Board of Curators - Fundação Butantan
André Franco Montoro Filho
Carlos Wendel de Magalhães
Erney F. Plessmann de Camargo
Fernando de Souza Meirelles
Gonzalo Vecina Neto
João Fernando Gomes da Oliveira
Jorge Kalil
Luiz R. Raja Gabaglia Travassos
Luiz Vicente Rizzo
Moisés Goldbaum
Paulo Lee Ho
Yara Cury
Finance Council - Fundação Butantan
Carlos Alberto Marsal
Israel Domingos Bacas
Joaquim José C. Engler
Geraldo Alckmin
Governor of the State
of São Paulo
David Uip
State Secretary of Health
Sergio Swain Muller
Science, Technology and
Strategical Health Products
Coordinator
Jorge Kalil
Director of Instituto Butantan
President of Fundação Butantan
Marcelo de Franco
Vice-director of Instituto Butantan